It was demonstrated that the application of anti-CD44, anti-CD82, and anti-CD98 monoclonal antibodies could block the adhesion between the microenvironment and AML cells, thereby inhibiting the survival of AML cells [86–88]. This evidence concerns the gene CD82 and acute myeloid leukemia.